Certara, Inc. 2026 Q3 - Results - Earnings Call Presentation
Certara, Inc. (CERT) Q3 2026 Earnings Call Transcript
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $12
Why Did Certara (CERT) Shares Climb After Its Latest Update?
Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand
Certara (CERT) Q3 2026 Earnings Call Transcript
Certara Q3 Earnings Call Highlights
Certara (NASDAQ:CERT) Posts In-Line Q3 as Software Growth Offsets Services Weakness
Certara Reports Third Quarter 2026 Financial Results
Certara Q3 2026 Earnings Call Transcript
Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoY
Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026
Certara (CERT) Stock May Trade Above Fair Value On Its 75% Slump
Keybanc Maintains Overweight on Certara, Raises Price Target to $12
Certara: Software Bookings Are Improving, But Cash Flow Has Yet To Follow
TD Cowen Maintains Buy on Certara, Raises Price Target to $11
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9
In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
UBS Downgrades Certara to Neutral, Maintains Price Target to $10
Certara (CERT) Slashes Jobs While Doubling Down On Software Growth
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.